Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors
- PMID: 10620629
- DOI: 10.1093/jnci/92.1.18
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors
Abstract
Background: Epigenetic factors (i.e., alterations of gene activity not involving mutations), as well as genetic changes in surviving cancer cells, may play an important role in drug resistance following cancer chemotherapy-a common cause of tumor relapse. Bcl-2 family proteins are central to the regulation of apoptotic cell death and modulate drug sensitivity. We investigated how survival signals in the cellular microenvironment affect the expression, protein conformation, and protein-protein interactions of the Bcl-2 family proteins Bax and Bcl-x(L) and how changes in response to microenvironmental signals alter the response of cancer cells to the drug etoposide.
Methods: JLP119 human B-lymphoma cells were treated with etoposide (40 microM) and then cultured in the presence of an activating anti-CD40 antibody, vascular cellular adhesion molecule-1 (VCAM-1)-to activate VLA-4 (alpha4beta1) integrin, and interleukin 4. Cell fate was monitored after etoposide treatment with or without these microenvironmental signals. Bcl-x(L) gene transcription and protein levels of Bcl-x(L) and Bax were measured by northern and western blotting, respectively. Nuclear translocation of transcription factor NF-kappaB was monitored by immunofluorescence and inhibited by (E)-capsaicin. Bax conformation and Bax-Bcl-x(L) interactions were monitored by immunofluorescence and immunoprecipitation, respectively.
Results: Microenvironmental survival signals produced statistically significant reductions in etoposide-induced apoptotic cell death, from 84.6% (95% confidence interval [CI] = 76.7%-92.4%) to 21.3% (95% CI = 19.5%-23.0%); P<.001. Activation of surface protein CD40 increased Bcl-x(L) protein levels via an (E)-capsaicin-inhibitable activation of NF-kappaB; i.e. , (E)-capsaicin restored etoposide sensitivity. Interleukin 4 had no effect on Bcl-x(L) protein levels but accelerated the increase in Bcl-x(L) protein associated with CD40 activation. VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.
Conclusions: Microenvironmental factors reduce the sensitivity of a B-cell lymphoma to etoposide in vitro by modulating the expression and functions of Bax and Bcl-x(L). This interaction may provide a paradigm for epigenetically induced drug resistance in other tumors.
Comment in
-
Genetic and epigenetic factors in anticancer drug resistance.J Natl Cancer Inst. 2000 Jan 5;92(1):4-5. doi: 10.1093/jnci/92.1.4. J Natl Cancer Inst. 2000. PMID: 10620620 No abstract available.
Similar articles
-
Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas.Endocr Relat Cancer. 1999 Mar;6(1):21-3. doi: 10.1677/erc.0.0060021. Endocr Relat Cancer. 1999. PMID: 10732782 Review.
-
Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins.Arch Virol. 2004 Feb;149(2):289-302. doi: 10.1007/s00705-003-0212-8. Epub 2003 Nov 4. Arch Virol. 2004. PMID: 14745596
-
Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells.Mol Cell Biochem. 2000 Mar;206(1-2):43-50. doi: 10.1023/a:1007056727876. Mol Cell Biochem. 2000. PMID: 10839193
-
Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax.Leukemia. 1999 Feb;13(2):266-74. doi: 10.1038/sj.leu.2401275. Leukemia. 1999. PMID: 10025901
-
Bax. The pro-apoptotic Bcl-2 family member, Bax.Int J Biochem Cell Biol. 1998 Jun;30(6):647-50. doi: 10.1016/s1357-2725(98)00006-5. Int J Biochem Cell Biol. 1998. PMID: 9695020 Review.
Cited by
-
Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance.J Exp Clin Cancer Res. 2013 Jun 1;32(1):36. doi: 10.1186/1756-9966-32-36. J Exp Clin Cancer Res. 2013. PMID: 23725446 Free PMC article.
-
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.Int J Mol Sci. 2014 Aug 8;15(8):13768-801. doi: 10.3390/ijms150813768. Int J Mol Sci. 2014. PMID: 25110867 Free PMC article. Review.
-
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Adv Pharmacol. 2012;65:335-59. doi: 10.1016/B978-0-12-397927-8.00011-7. Adv Pharmacol. 2012. PMID: 22959031 Free PMC article. Review.
-
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.Clin Exp Metastasis. 2002;19(1):55-60. doi: 10.1023/a:1013880326925. Clin Exp Metastasis. 2002. PMID: 11918083
-
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.Cancer Drug Resist. 2019 Sep 19;2(3):490-515. doi: 10.20517/cdr.2019.57. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582567 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous